Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas

NCT02283658 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02283658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02283658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
November 14, 2014
Completion date
June 21, 2018
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent ovarian germ cell tumor, recurrent primary peritoneal carcinoma, undifferentiated ovarian carcinoma